Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PPME1 | Q9Y570 | 1/20 | 0.47 |
| ▸ | RRM1 | P23921 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | RXFP3 | Q9NSD7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635746 | 1.00 | MAPT (0.49) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5636404 | 0.84 | MAPT (0.55) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5636407 | 0.84 | MAPT (0.55) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL3246996 | 0.83 | APP (0.56) | MAPTPOLBMEN1KMT2ARRM1 | |
| SCHEMBL5636909 | 0.81 | MAPT (0.48) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5634721 | 0.81 | RXFP3 (0.52) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5636906 | 0.81 | MAPT (0.48) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5634720 | 0.81 | RXFP3 (0.52) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5635376 | 0.81 | PPME1 (0.48) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL5635380 | 0.81 | PPME1 (0.48) | MAPTPOLBMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | claimed |
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | US | disclosed |
| EP-1689710-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051908-A1 | INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER | NOVO NORDISK A/S (DK) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010559-A1 | Indole derivatives for use as chemical uncoupler | GPR119, IDO2, IDO1 | MAPT 4316/4885POLB 4671/4885MEN1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.